

## CURRICULUM VITAE

<b>Name:</b>												
Peter W.M Johnson												
<b>Summary:</b>												
<p>Professor of Medical Oncology at University of Southampton          Trained in Medical Oncology at St Bartholomew's Hospital in London and was Senior Lecturer in the Cancer Centre at Leeds.</p> <p>Research interests in applied immunology and immunotherapy, lymphoma biology and clinical trials. Chief Investigator for lymphoma trials ranging from first in man novel antibody therapeutics to international randomised studies, and for the Cancer Research UK Stratified Medicine Programme. Leading the Grail-NHS collaboration on blood borne markers for early cancer detection.</p>												
<b>Qualifications:</b>												
<table border="0"> <tr> <td>F Med. Sci.</td> <td>London</td> <td>2014</td> </tr> <tr> <td>FRCP</td> <td>London</td> <td>1998</td> </tr> <tr> <td>MD</td> <td>University of Cambridge</td> <td>1994</td> </tr> <tr> <td>MB B.Chir</td> <td>University of Cambridge</td> <td>1985</td> </tr> </table>	F Med. Sci.	London	2014	FRCP	London	1998	MD	University of Cambridge	1994	MB B.Chir	University of Cambridge	1985
F Med. Sci.	London	2014										
FRCP	London	1998										
MD	University of Cambridge	1994										
MB B.Chir	University of Cambridge	1985										
<b>Present Post:</b>												
<p>From August 1998:          Professor of Medical Oncology, University of Southampton Faculty of Medicine.          Honorary Consultant in Medical Oncology, Southampton University Hospitals NHS Trust.</p> <p>From October 2019:          National Clinical Director for Cancer, NHS England</p>												
<b>Previous appointments:</b>												
<p>Jan 2008-Oct 2017: Chief Clinician – Cancer Research UK          Apr 1994-Jul 1998 – Senior Lecturer in Medical Oncology – University of Leeds          Aug 1989-Mar 1994 –ICRF Clinical Research Fellow – St Bartholomew's Hospital, London</p>												
<b>National/International committees:</b>												
<ul style="list-style-type: none"> <li>• National Cancer Research Institute, Board 2008-2015, Trustee 2015-2017</li> <li>• Academy of Medical Sciences Review of Research Governance and Regulation 2010-2011</li> <li>• NHS Chief Executive Review of Innovation: External Advisory Group 2011</li> <li>• Cancer Immunotherapy (CIMT) Consortium, Executive Board 2008-2015</li> <li>• UK Clinical Research Collaboration, Board 2009-2017</li> <li>• Genomics England Ltd Scientific Advisory Committee 2013-2016</li> <li>• International Conference on Malignant Lymphoma: Scientific Committee 2008-</li> <li>• International advisor, Schweiz. Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK) 2010-</li> <li>• Institut Suisse de Recherche Expérimentale sur le Cancer (ISREC) Foundation_Scientific Board 2015-</li> <li>• Cyprus Cancer Research Institute: Scientific Advisory Board, 2019-2022</li> <li>• Royal College of Physicians Joint Specialty Committee on Medical Oncology, Chair 2018-2022</li> </ul>												
<b>Academic activities:</b>												
<p><b>Research Output and Dissemination:</b></p> <ul style="list-style-type: none"> <li>• 80 invited lectures since 2010</li> <li>• Over 200 peer-reviewed papers including New Eng J Med (3), Lancet (3), Immunity (1), Cancer Cell (3), J Clin Oncol (21), Lancet Oncology (7) Blood (26). H-index 82.</li> </ul> <p><b>Postgraduate Research Training:</b></p> <ul style="list-style-type: none"> <li>• 25 PhD or MD's graduated since 2005</li> </ul>												
<b>Current Research Grants:</b>												
<p>Southampton Centre and training accounts (Lead applicant) 2017-2023. Cancer Research UK <b>£6.65M</b>          Molecular analysis of the success determinants and mechanisms of solid tumour immunotherapy. (Lead applicant) 2016-2022. Cancer Research UK Centres Accelerator Award <b>£4M</b>          Southampton Experimental Cancer Medicine Centre (co-applicant) 2017-2022. NIHR/CRUK <b>£2M</b>          Understanding Fc gamma receptors to improve antibody immunotherapy (co-applicant) 2017-2023. Cancer Research UK <b>£2.2M</b>          B-cell receptor signalling in B-cell malignancies: Identifying strategies for optimal therapeutic intervention based on common and distinct responses. (co-applicant) 2017-2023. Cancer Research UK <b>£1.5M</b>          iDx Lung: Integrated biomarker studies (Lead Applicant). 2020-2023 Innovate UK <b>£3.14M</b></p>												

## Recent publications:

- Bewicke-Copley F, Korfi K, Araf S, et al., Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type Diffuse Large B Cell Lymphoma. **Blood Adv.** 2022 Aug 10
- Lee LYW, Starkey T, Ionescu MC, et al., Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study. **Lancet Oncol.** 2022;S1470-2045(22)00202-9
- Lim SH, Stuart B, Joseph-Pietras D, et al., Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study. **Nat Cancer.** 2022 May;3(5):552-564
- Hutchings M, Mous R, Clausen MR, Johnson P et al., Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. **Lancet.** 2021;398:1157-1169.
- Lim SH, Campbell N, Johnson M, et al., Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma. **Lancet Haematol.** 2021;8(8):e542-e544
- Heward JA, Koniali L, D'Avola A, et al., JKDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas. **Blood.** 2021; 138(5):370-81
- Clift AK, Coupland CAC, Keogh RH, et al., Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. **BMJ.** 2020 Oct 20;371:m3731
- Clark JJ, Dwyer D, Pinwill N, Clark P, Johnson P, Hackshaw A. The effect of clinical decision making for initiation of systemic anticancer treatments in response to the COVID-19 pandemic in England: a retrospective analysis. **Lancet Oncol.** 2020;S1470-2045(20)30619-7.
- Cummin TEC, Cox KL, Murray TD, et al., BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression. **Blood Adv.** 2020;4(14):3316-3328
- Sha C, Barrans S, Cucco F, et al., Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy. **J Clin Oncol.** 2019;37(3):202-212
- Yap TA, Winter JN, Giulino-Roth L, et al., Phase 1 study of the novel enhancer of zeste homolog 2 (EZH2) inhibitor GSK2816126 in patients with advanced hematological and solid tumors. **Clin Cancer Res.** 2019;25(24):7331-7339
- Ansell SM, Minnema MC, Johnson P, et al., Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study. **J Clin Oncol.** 2019;37(6):481-489
- Younes A, Sehn LH, Johnson P, et al., Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. **J Clin Oncol.** 2019; 37(15):1285-1295
- Davies A, Cummin TE, Barrans S, et al., Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. **Lancet Oncol.** 2019;20(5):649-662
- Drennan S, Chiodin G, D'Avola A, et al., Ibrutinib therapy releases leukemic surface IgM from antigen drive in chronic lymphocytic leukemia patients. **Clin Cancer Res.** 2019;25(8):2503-2512
- Ceriani L, Milan L, Martelli M, et al., Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma. **Blood** 2018; 132:179-186.
- Buchan SL, Dou L, Remer M, et al., Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function. **Immunity.** 2018;49(5):958-970.e7
- Anderson RA, Remedios R, Kirkwood AA, et al., Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial. **Lancet Oncol.** 2018;19(10):1328-1337.
- Turaj AH, Hussain K, Cox KL, et al., Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment. **Cancer Cell.** 2017;32:777-791
- Ferreri AJM, Cwynarski K, Pulczynski E, et al., Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. International Extranodal Lymphoma Study Group (IELSG). **Lancet Haematol.** 2017 Nov;4(11): e510-e523
- Zucca E, Conconi A, Martinelli G, et al., Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. **J Clin Oncol.** 2017;35(17):1905-1912
- P.W.M. Johnson, M. Federico, A.A. Kirkwood, et al., Adapted Treatment Guided by Interim PET Scan in Advanced Hodgkin's Lymphoma. **New Engl J Med,** 2016. 374:2419-29
- Barrington SF, Kirkwood AA, Franceschetto A, et al., . PET-CT for Staging & Early Response: Results from 'Response Adapted Therapy in Advanced Hodgkin Lymphoma' (RATHL) (CRUK/07/033) **Blood** 2016; 127(12):1531-1538.
- Aguilar-Hernandez MM, Blunt MD, Dobson R, et al., IL-4 enhances expression and function of surface IgM in CLL cells. **Blood.** 2016, 127:3015-25.
- Okosun J, Wolfson RL, Wang Jet al., Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. **Nature Genetics.** 2016 Feb;48:183-8

